BridgeBio Pharma (BBIO) Expected to Announce Earnings on Tuesday

BridgeBio Pharma (NASDAQ:BBIO) will likely be issuing its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of ($0.71) per share and revenue of $178.6280 million for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The firm had revenue of $154.18 million during the quarter, compared to analysts’ expectations of $150.71 million. During the same period in the prior year, the firm earned ($1.40) earnings per share. BridgeBio Pharma’s revenue for the quarter was up 2521.2% on a year-over-year basis. On average, analysts expect BridgeBio Pharma to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BridgeBio Pharma Price Performance

Shares of BridgeBio Pharma stock traded down $1.22 during trading hours on Tuesday, reaching $73.30. The company had a trading volume of 5,192,442 shares, compared to its average volume of 2,642,658. BridgeBio Pharma has a one year low of $31.77 and a one year high of $84.94. The business has a fifty day simple moving average of $71.45 and a 200 day simple moving average of $70.74. The firm has a market cap of $14.21 billion, a PE ratio of -19.56 and a beta of 1.09.

Insiders Place Their Bets

In related news, Director Andrea Ellis sold 64,921 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $64.87, for a total value of $4,211,425.27. Following the transaction, the director owned 18,589 shares of the company’s stock, valued at $1,205,868.43. This represents a 77.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Neil Kumar sold 40,000 shares of the stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $71.94, for a total value of $2,877,600.00. Following the completion of the transaction, the chief executive officer directly owned 695,686 shares in the company, valued at approximately $50,047,650.84. This represents a 5.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 237,084 shares of company stock valued at $16,634,419 over the last quarter. Insiders own 18.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BBIO. Jones Financial Companies Lllp bought a new position in BridgeBio Pharma in the first quarter valued at $35,000. First Trust Advisors LP boosted its position in BridgeBio Pharma by 200.4% during the second quarter. First Trust Advisors LP now owns 263,693 shares of the company’s stock valued at $11,386,000 after buying an additional 175,918 shares during the period. Baird Financial Group Inc. boosted its position in BridgeBio Pharma by 1.8% during the second quarter. Baird Financial Group Inc. now owns 42,057 shares of the company’s stock valued at $1,816,000 after buying an additional 731 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in BridgeBio Pharma during the second quarter valued at about $1,650,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in BridgeBio Pharma by 2.4% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,326 shares of the company’s stock valued at $4,132,000 after buying an additional 2,206 shares during the period. Institutional investors own 99.85% of the company’s stock.

Analyst Ratings Changes

BBIO has been the topic of several research analyst reports. Barclays reaffirmed an “overweight” rating on shares of BridgeBio Pharma in a report on Tuesday, March 10th. Truist Financial upped their price target on shares of BridgeBio Pharma from $86.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Royal Bank Of Canada initiated coverage on shares of BridgeBio Pharma in a report on Thursday, April 9th. They issued an “outperform” rating and a $100.00 price target on the stock. Oppenheimer decreased their price target on shares of BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating on the stock in a report on Wednesday, February 25th. Finally, Mizuho reaffirmed an “outperform” rating and issued a $106.00 price target on shares of BridgeBio Pharma in a report on Tuesday. Twenty-four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $87.38.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.